

8th Chinese German Lung Cancer Forum

Dresden, Germany, September 8-10, 2016

Precision oncology in lung cancer

Thursday, September 8, 2016

17:00 – 17:45 Meet-the-Professor – Immuno-Oncology
Fan Yang, Beijing, Christoph Zielinski, Vienna

18:00 – 18:45 Meet-the Professor – Molecular Pathology
Caicun Zhou, Shanghai, Mauro Papotti, Torino

Friday, September 9, 2016

08:30 Welcome address

Moderation: Yi-Long Wu, Guangzhou, Christian Manegold, Mannheim

Xiao Zhou, Shanghai, Jacek Niklinski, Bialystok, Rudolf M. Huber, Munich, Jürgen Wolf, Cologne

09:00 Tobacco Control

Chairs: Xin Wang, Beijing, Lothar Pilz, Mannheim

E-cigarette aerosol and nicotine exposure

Manfred Neuberger, Vienna

Smoking cessation in young people

Anneke Bühler, Munich

Tobacco control: The Chinese policy

Xin Wang, Beijing

Discussion:

All

09:45 Pathology/Molecular biology

Chairs: Jiuwei Cui, Changchun, Martin Sos, Cologne

New generation sequencing techniques

Lukas Heukamp, Cologne

Diagnostic issues: Cytology, tissue, liquid biopsy

Agata Pilaszewicz-Puza, Bialystok

Molecular testing in China
Jiuwei Cui, Changchun

Discussion:
All

10:30 Coffee break

10:45 Lung Cancer Screening/Innovative Imaging

Chairs: Jie Hu, Shanghai, Manfred Neuberger, Vienna

Economics and management of lung disease
Larissa Schwarzkopf, Munich

Lung cancer screening based on modern imaging
Jochen Dormeier, Erlangen

Modern lung cancer staging
Sonja Sudarski, Mannheim

New PET – Tracer
Björn Wängler, Mannheim

Lung cancer screening in China
Jie Hu, Shanghai

Discussion:
All

11:45 Radiotherapy in lung cancer

Chairs: Zhengfei Zhu, Shanghai; Frank Giordano, Mannheim;

Interaction between targeted agents and radiotherapy
Anna Wrona, Gdansk

Current issues in lung cancer radiotherapy in China
Zhengfei Zhu, Shanghai

Interventional radiology
Michael Kostrzewa, Mannheim,

Radiotherapy of brain metastasis: innovative approaches
Frank Giordano, Mannheim

Discussion:
All

12:45 Lunch

13:45 Surgery

Chairs: Keneng Chen, Beijing; Eric Rößner, Mannheim

Cross-border surgery of thoracic, plastic-reconstructive, and upper GI surgeons
Peter Hohenberger, Mannheim

Precision management of stage III NSCLC: The surgeon's position
Michael Rolf Müller, Vienna

Current issues in lung cancer surgery
Keneng Chen, Beijing

VATS, CATS, and RATS for diagnosis and treatment of lung cancer
Eric Rößner, Mannheim

Personalized lung cancer surgery contributes to precise medicine
Wenzhao Zhong, Guangzhou

Discussion:

All

15:15 Biostatistics/Clinical Trials/Legal aspects

Chairs: Yi-Long Wu, Guangzhou, Lothar Pilz, Mannheim

Clinical trials in lung cancer 2016: Considerations for precision medicine
Lothar Pilz, Mannheim

Clinical Trials in China: Contribution in global drug development
Yi-Long Wu, Guangzhou

Conflict preparation and conflict solution in medical environments
Karl Brandt, Hamburg

Discussion:

All

16:00 Immunotherapy

Chairs: Yusong Zhang, Suzhou; Florian Kron, Cologne

Is there still room for vaccines in lung cancer therapy?
Marcin Moniuszko, Bialystok

Checkpoint inhibitors in lung cancer therapy
Jürgen Wolf, Cologne

Immune checkpoint inhibitors: Costs effective strategies
Florian Kron, Cologne

Discussion:

All

16.45 **Coffee break**

17:00 **MicroRNA in thoracic oncology;**

Chairs: Nico van Zandwijk, Sydney; Marcin Moniuszko, Bialystok

Micro-RNA expression in lung cancer

Urmo Võsa, Tartu

Novel molecular therapeutic possibilities for lung cancer

Anna Rusek, Bialystok

MicroRNA based therapy in thoracic tumors – personal experience

Nico van Zandwijk, Sydney

Chinese experience with microRNA in thoracic oncology

Fengying Wu, Shanghai

Discussion:

All

18:00 **Uncommon thoracic tumors**

Chairs: Xiaohui Chen, Fujian; Monika Serke, Hemer

Role of surgery in SCLC

Mirosław Kozłowski, Białystok

ProGRP as a biomarker for clinical response evaluation in SCLC

Thomas Muley, Heidelberg

Treatment of SCLC: Chinese experience

Xiance Jin, Wenzhou

Malignant pleural mesothelioma – precision oncology in 2016

Monika Serke, Hemer

Thymoma and thymic carcinomas – a critical review of WHO classification

Alexander Marx, Mannheim

Discussion:

All

19:00 Management of advanced NSCLC

Chairs: Caicun Zhou, Shanghai; Robert Pirker, Vienna

Personalized first-line therapy in 2016

Robert Pirker, Vienna

Targeted therapy in China

Fan Yang, Beijing

Issues of drug resistance in targeted therapy

Martin Sos, Cologne

New anti-angiogenic agents in second-line therapy: Ramucirumab, nintedanib

Rudolf M. Huber, Munich

Treatment of advanced squamous cell carcinoma of the lung

Jie Hu, Shanghai

Treatment strategies after progression of first-line therapy

Yusong Zhang, Suzhou

Discussion: **All**

20:30 Housekeeping notes

Christian Manegold, Mannheim

Saturday, September 10, 2016

07:00 – 08:00 Meet-the-Professor – Radiotherapy:
Hong Zhao, Beijing, Frank Giordano, Mannheim

08:00 Young Investigators Session

Chairs: **Sabine Zöchbauer-Müller, Vienna; Yi-Long Wu, Guangzhou**

Surgery for multiple primary lung cancer

Xiaohui Chen, Fujian

Mutual relationship between cancer and immune cells

Andrzej Eljaszewicz, Bialystok

VEGFR-small molecular inhibitors in lung cancer

Fengying Wu, Shanghai

Overcoming resistance to EGFR-TKI therapy

Sebastian Michels, Cologne

Interaction of erythropoietine-receptor –system and angiogenesis

Xiaoqing Liu, Munich

Prognostic value of immune score in resected NSCLC

Julia Stump, Munich

Discussion:

All

10:00

Closing remarks

Caicun Zhou, Shanghai; Christian Manegold, Mannheim